The American pharmaceutical company Gilead Sciences will buy Immunomedics for $ 21 billion (CZK 471 billion). This will give him access to a promising drug, thus strengthening his cancer drugs division. The companies announced this in a joint communication.
–
Under the agreement, Gilead will have access to the drug Trodelvy, which Immunomedics has developed to treat an aggressive and difficult-to-treat type of breast cancer. In April, the drug was approved by the US Food and Drug Administration (FDA).
–
Gilead said it is offering $ 88 per share of Immunomedics, 108 percent more than the stock sold at the end of Friday’s trading on Friday. The deal was announced on Sunday and should be completed in the fourth quarter of this year, the companies said.
–
Gilead has been expanding its portfolio of oncology drugs very significantly in recent months. In March, the company announced an agreement to acquire Forty Seven for $ 4.9 billion. In May, he agreed to conclude a ten-year cooperation agreement with Arcus Biosciences, and in June he announced the purchase of a stake in Pionyr Immunotherapeutics.
–
This year, Gilead Sciences became known mainly for Remdesivir for the treatment of the more severe course of covid-19 disease caused by a new type of coronavirus. A team of experts led by the Czech biochemist Tomáš Cihlář participated in the development of the product in Gilead.
—
